Harry Paul Erba, MD, PhD

Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address harry.erba@duke.edu

I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine.  I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies.  I am also the Chair of the SWOG Leukemia Committee.  I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia.  Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.  

Education and Training

  • Research Fellowship in Medicine, Medicine, Harvard Medical School, 1991 - 1993
  • Research/Clinical Fellowship in Medicine, Medicine, Brigham and Women's Hospital, 1991 - 1992
  • Clinical Fellow in Medicine, Medicine, Harvard Medical School, 1988 - 1991
  • Residency Physician, Medicine, Brigham and Women's Hospital, 1988 - 1990
  • Ph.D., Stanford University, 1988
  • M.D., Stanford University, School of Medicine, 1988

Grants

Publications

Uy, Geoffrey L., Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, et al. “Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.” Blood, September 14, 2020. https://doi.org/10.1182/blood.2020007732.

PMID
32929488
Full Text

Shah, Gaurav, Fady M. Mikhail, Kimo Bachiasvili, Pankit Vachhani, Harry P. Erba, and Nikolaos Papadantonakis. “Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.” Hematol Oncol Stem Cell Ther 13, no. 3 (September 2020): 143–46. https://doi.org/10.1016/j.hemonc.2019.08.006.

PMID
31629725
Full Text

Sekeres, Mikkael A., Gordon Guyatt, Gregory Abel, Shabbir Alibhai, Jessica K. Altman, Rena Buckstein, Hannah Choe, et al. “American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.” Blood Adv 4, no. 15 (August 11, 2020): 3528–49. https://doi.org/10.1182/bloodadvances.2020001920.

PMID
32761235
Full Text

Zeidan, Amer M., Prajwal C. Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal, Rory Shallis, et al. “Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.” Lancet Haematol 7, no. 8 (August 2020): e601–12. https://doi.org/10.1016/S2352-3026(20)30205-2.

PMID
32563283
Full Text

Othus, Megan, Aasthaa Bansal, Harry Erba, and Scott Ramsey. “Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up.” Value Health 23, no. 8 (August 2020): 1034–39. https://doi.org/10.1016/j.jval.2020.02.015.

PMID
32828215
Full Text

Pagel, John M., Megan Othus, Guillermo Garcia-Manero, Min Fang, Jerald P. Radich, David A. Rizzieri, Guido Marcucci, et al. “Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.” Jco Oncol Pract 16, no. 6 (June 2020): e464–75. https://doi.org/10.1200/JOP.19.00133.

PMID
32048933
Full Text

Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol 95, no. 6 (June 2020): 662–71. https://doi.org/10.1002/ajh.25781.

PMID
32162718
Full Text

Lancet, Jeffrey E., Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, and Frederick R. Appelbaum. “A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).” Blood Advances 4, no. 8 (April 2020): 1683–89. https://doi.org/10.1182/bloodadvances.2019001278.

PMID
32330241
Full Text

Roboz, Gail J., Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.” Blood 135, no. 7 (February 13, 2020): 463–71. https://doi.org/10.1182/blood.2019002140.

PMID
31841594
Full Text

Merz, Lauren E., Anthony J. Perissinotti, Bernard L. Marini, Patrick W. Burke, Ashley Crouch, Harry P. Erba, and Dale Bixby. “Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.” Clin Lymphoma Myeloma Leuk 20, no. 1 (January 2020): 24–30. https://doi.org/10.1016/j.clml.2019.09.615.

PMID
31711889
Full Text

Pages